7 results on '"Falkard, Brie"'
Search Results
2. Rapid HIV‐1 genotyping assay for the detection of capsid mutations.
- Author
-
Margot, Nicolas, Naik, Vidula, Nekkalapudi, Anurag, Boopathy, Archana, Falkard, Brie, and Callebaut, Christian
- Subjects
HIV ,ANTI-HIV agents ,HOSPITAL laboratories ,VIRAL proteins ,TREATMENT failure - Abstract
Human immunodeficiency virus (HIV) capsid is one of the most recent viral proteins successfully targeted for the development of antiretrovirals. Lenacapavir is a first in class HIV‐1 capsid inhibitor that was recently approved for the treatment of highly treatment‐experienced people with HIV in combination with other anti‐HIV drugs. Owing to the novelty of the viral target, methods to characterize the potential resistance‐associated mutations present in capsid upon treatment failure have not been fully established yet. Here, we describe a rapid and simple method to amplify capsid fragments and to determine their sequence from various clinical samples including diverse HIV‐1 subtypes. These methods could easily be implemented in laboratories, including hospital laboratories often caring for this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysacchide in Haitian adults.
- Author
-
Falkard, Brie, Charles, Richelle C., Matias, Wilfredo R., Mayo-Smith, Leslie M., Jerome, J. Gregory, Offord, Evan S., Xu, Peng, Kováč, Pavol, Ryan, Edward T., Qadri, Firdausi, Franke, Molly F., Ivers, Louise C., and Harris, Jason B.
- Subjects
- *
B cells , *ORAL vaccines , *ANTIBODY formation , *MEMORY , *CHOLERA vaccines , *IMMUNOGLOBULIN producing cells - Abstract
The bivalent killed whole-cell oral cholera vaccine (BivWC) is being increasingly used to prevent cholera. The presence of O-antigen-specific memory B cells (MBC) has been associated with protective immunity against cholera, yet MBC responses have not been evaluated after BivWC vaccination. To address this knowledge gap, we measured V. cholerae O1-antigen MBC responses following BivWC vaccination. Adults in St. Marc, Haiti, received 2 doses of the BivWC vaccine, Shanchol, two weeks apart. Participants were invited to return at days 7, 21, 44, 90, 180 and 360 after the initial vaccination. Serum antibody and MBC responses were assessed at each time-point before and following vaccination. We observed that vaccination with BivWC resulted in significant O-antigen specific MBC responses to both Ogawa and Inaba serotypes that were detected by day 21 and remained significantly elevated over baseline for up to 12 months following vaccination. The BivWC oral cholera vaccine induces durable MBC responses to the V. cholerae O1-antigen. This suggests that long-term protection observed following vaccination with BivWC could be mediated or maintained by MBC responses. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults.
- Author
-
Matias, Wilfredo R., Falkard, Brie, Charles, Richelle C., Mayo-Smith, Leslie M., Teng, Jessica E., Xu, Peng, Kováč, Pavol, Ryan, Edward T., Qadri, Firdausi, Franke, Molly F., Ivers, Louise C., and Harris, Jason B.
- Subjects
- *
PREVENTION of cholera , *IMMUNE response , *VACCINATION , *ANTIGENS , *VIBRIO infections - Abstract
Background: The bivalent whole-cell (BivWC) oral cholera vaccine (Shanchol) is effective in preventing cholera. However, evaluations of immune responses following vaccination with BivWC have been limited. To determine whether BivWC induces significant mucosal immune responses, we measured V. cholerae O1 antigen-specific antibody secreting cell (ASC) responses following vaccination. Methodology/Principal Findings: We enrolled 24 Haitian adults in this study, and administered doses of oral BivWC vaccine 14 days apart (day 0 and day 14). We drew blood at baseline, and 7 days following each vaccine dose (day 7 and 21). Peripheral blood mononuclear cells (PBMCs) were isolated, and ASCs were enumerated using an ELISPOT assay. Significant increases in Ogawa (6.9 cells per million PBMCs) and Inaba (9.5 cells per million PBMCs) OSP-specific IgA ASCs were detected 7 days following the first dose (P < 0.001), but not the second dose. The magnitude of V. cholerae-specific ASC responses did not appear to be associated with recent exposure to cholera. ASC responses measured against the whole lipolysaccharide (LPS) antigen and the OSP moiety of LPS were equivalent, suggesting that all or nearly all of the LPS response targets the OSP moiety. Conclusions/Significance: Immunization with the BivWC oral cholera vaccine induced ASC responses among a cohort of healthy adults in Haiti after a single dose. The second dose of vaccine resulted in minimal ASC responses over baseline, suggesting that the current dosing schedule may not be optimal for boosting mucosal immune responses to V. cholerae antigens for adults in a cholera-endemic area. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. Parasite-induced ER stress response in hepatocytes facilitates Plasmodium liver stage infection.
- Author
-
Inácio, Patricia, Zuzarte‐Luís, Vanessa, Ruivo, Margarida TG, Falkard, Brie, Nagaraj, Nagarjuna, Rooijers, Koos, Mann, Matthias, Mair, Gunnar, Fidock, David A, and Mota, Maria M
- Abstract
Upon infection of a mammalian host, Plasmodium parasites first replicate inside hepatocytes, generating thousands of new parasites. Although Plasmodium intra-hepatic development represents a substantial metabolic challenge to the host hepatocyte, how infected cells respond to and integrate this stress remains poorly understood. Here, we present proteomic and transcriptomic analyses, revealing that the endoplasmic reticulum ( ER)-resident unfolded protein response ( UPR) is activated in host hepatocytes upon Plasmodium berghei infection. The expression of XBP1s-the active form of the UPR mediator XBP1-and the liver-specific UPR mediator CREBH is induced by P. berghei infection in vivo. Furthermore, this UPR induction increases parasite liver burden. Altogether, our data suggest that ER stress is a central feature of P. berghei intra-hepatic development, contributing to the success of infection. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Plasma Leptin Levels in Children Hospitalized with Cholera in Bangladesh.
- Author
-
Falkard, Brie, Uddin, Taher, Rahman, M. Arifur, Franke, Molly F., Aktar, Amena, Uddin, Muhammad Ikhtear, Bhuiyan, Taufiqur Rahman, Leung, Daniel T., Charles, Richelle C., Larocque, Regina C., Harris, Jason B., Calderwood, Stephen B., Qadri, Firdausi, and Ryan, Edward T.
- Published
- 2015
- Full Text
- View/download PDF
7. Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.
- Author
-
Boopathy AV, Nekkalapudi A, Sung J, Schulha S, Jin D, Sharma B, Ng S, Lu S, Wimmer R, Suthram S, Ahmadi-Erber S, Lauterbach H, Orlinger KK, Hung M, Carr B, Callebaut C, Geleziunas R, Kuhne M, Schmidt S, and Falkard B
- Abstract
Arenaviral vaccine vectors encoding simian immunodeficiency virus (SIV) immunogens are capable of inducing efficacious humoral and cellular immune responses in nonhuman primates. Several studies have evaluated the use of immune modulators to further enhance vaccine-induced T-cell responses. The hematopoietic growth factor Flt3L drives the expansion of various bone marrow progenitor populations, and administration of Flt3L was shown to promote expansion of dendritic cell populations in spleen and blood, which are targets of arenaviral vectors. Therefore, we evaluated the potential of Flt3 signaling to enhance the immunogenicity of arenaviral vaccines encoding SIV immunogens (SIV
SME543 Gag, Env, and Pol) in rhesus macaques, with a rhesus-specific engineered Flt3L-Fc fusion protein. In healthy animals, administration of Flt3L-Fc led to a 10- to 100-fold increase in type 1 dendritic cells 7 days after dosing, with no antidrug antibody (ADA) generation after repeated dosing. We observed that administration of Flt3L-Fc fusion protein 7 days before arenaviral vaccine increased the frequency and activation of innate immune cells and enhanced T-cell activation with no treatment-related adverse events. Flt3L-Fc administration induced early innate immune activation, leading to a significant enhancement in magnitude, breadth, and polyfunctionality of vaccine-induced T-cell responses. The Flt3L-Fc enhancement in vaccine immunogenicity was comparable to a combination with αCTLA-4 and supports the use of safe and effective variants of Flt3L to augment therapeutic vaccine-induced T-cell responses.IMPORTANCEInduction of a robust human immunodeficiency virus (HIV)-specific CD4+ and CD8+ T-cell response through therapeutic vaccination is considered essential for HIV cure. Arenaviral vaccine vectors encoding simian immunodeficiency virus (SIV) immunogens have demonstrated strong immunogenicity and efficacy in nonhuman primates. Here, we demonstrate that the immunogenicity of arenaviral vectors encoding SIV immunogens can be enhanced by administration of Flt3L-Fc fusion protein 7 days before vaccination. Flt3L-Fc-mediated increase in dendritic cells led to robust improvements in vaccine-induced T- and B-cell responses compared with vaccine alone, and Flt3L-Fc dosing was not associated with any treatment-related adverse events. Importantly, immune modulation by either Flt3L-Fc or αCTLA-4 led to comparable enhancement in vaccine response. These results indicate that the addition of Flt3L-Fc fusion protein before vaccine administration can significantly enhance vaccine immunogenicity. Thus, safe and effective Flt3L variants could be utilized as part of a combination therapy for HIV cure.- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.